We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Adaptive Biotechnologies Corporation | NASDAQ:ADPT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.08 | 2.73% | 3.01 | 2.91 | 4.79 | 3.14 | 2.95 | 2.99 | 1,094,025 | 05:00:01 |
By Josh Beckerman
Adaptive Biotechnologies Corp. said the U.S. Food and Drug Administration issued an Emergency Use Authorization for T-Detect COVID to confirm recent or prior Covid-19 infection.
Shares were recently up 18% to $50 after hours.
The company said the T-cell-based based test is the first indication resulting from Adaptive's TCR-Antigen Map collaboration with Microsoft Corp.
"People who have been unsure about a prior infection will now have another way to know if they had the virus," the company said. "We have proven that it is possible to read how T cells detect disease in the blood, and this is just the beginning of a pipeline of tests for many other indications," the company said.
The EUA was based on a clinical validation study showing that T-Detect COVID demonstrated sensitivity of 97.1% from date of diagnosis using RT-PCR, Adaptive said.
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
March 05, 2021 19:13 ET (00:13 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Adaptive Biotechnologies Chart |
1 Month Adaptive Biotechnologies Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions